A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia

A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia

Objective: This double-blind, placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate + prednisone (abiraterone) to prednisone alone in chemotherapy-naïve, asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients...

Full description

Bibliographic Details
Main Authors: Dingwei Ye, Yiran Huang, Fangjian Zhou, Keji Xie, Vsevolod Matveev, Changling Li, Boris Alexeev, Ye Tian, Mingxing Qiu, Hanzhong Li, Tie Zhou, Peter De Porre, Margaret Yu, Vahid Naini, Hongchuan Liang, Zhuli Wu, Yinghao Sun
Format: Article
Language:English
Published: Elsevier 2017-04-01
Series:Asian Journal of Urology
Subjects:
Abiraterone
Chemotherapy-naïve
Metastatic castration-resistant prostate cancer
Prostate specific antigen
Prednisone
Online Access:http://www.sciencedirect.com/science/article/pii/S2214388217300164

Internet

http://www.sciencedirect.com/science/article/pii/S2214388217300164

Similar Items